Jack Shern

Pediatric Oncologist. Sarcoma translational researcher. Camp Fantastic Superfan. Dad. @NCI_CCR_PedsOnc. #ChildhoodCancer. All comments are my own.

[Taylor Sundby, MD 🧬 @rtsundby]

19/ Please visit https://t.co/JoGg6X0T9N for the full story and list of amazing contributors like @bega_murray @bvantine1 and many other twitter-less collaborators!

[National Cancer Institute @theNCI]

Children and AYAs with newly diagnosed soft tissue sarcomas who are receiving care at a @COGorg member site are now eligible to enroll in the CCDI Molecular Characterization Initiative. Find out more. https://t.co/SIN5edMcDr #Data4ChildhoodCancer

[Jack Shern @jack_shern]

@theNCI @COGorg This is big news for pediatric patients with soft tissue sarcomas. Thanks to all at #CCDI and @COGorg who worked to get this open. Tell your friends and lets get this profiling done for all of our patients!

[National Cancer Institute @theNCI]

JUST ANNOUNCED: NCI's Childhood Cancer Data Initiative (#CCDI) launches the Molecular Characterization Initiative for #ChildhoodCancer research to foster data sharing through comprehensive cancer analysis. Learn more: https://t.co/mJqwRq2r1g #Data4ChildhoodCancer @NCIResearchCtr

[Kelly Carpenter @Hockey_NF_Mom]

Some fun pictures from virtual Camp Fantastic Tues and Wed. #imwithTravis #TeamTravis #EndNF #ikNowaFighter

[Javed Khan @JavedKhanOmics]

Genomic Classification and Clinical Outcome in Rhabdomyosarcoma: A Report From an International Consortium https://t.co/oXFWqeMYkk Excited to report on the results of many years of work and which will impact therapy for patients with rhabdomyosarcoma.

[Dr. Anthony Letai @NCIDirector]

We're making great progress on @theNCI’s Childhood #CancerData Initiative (CCDI).

An important part of the CCDI is the National #ChildhoodCancer Registry (NCCR), which uses 23 registries to identify and follow children and AYAs with cancer in the U.S.

https://t.co/GtMRvBGRu8

[Jack Shern @jack_shern]

Hoping that this work will continue to move molecular and genetic profiling of pediatric tumors into the clinic to improve outcomes for our patients #childhoodcancer

[Jack Shern @jack_shern]

Genomic Classification and Clinical Outcome in Rhabdomyosarcoma: A Report From an International Consortium https://t.co/SMBYmZwMsP

[Jack Shern @jack_shern]

What a great collaborative team @khanjavNCI @ShipleyLab @COGorg working to make progress in #Rhabdomyosarcoma

[Andrew Kaczynski @KFILE]

Every single damn day there is another child like Francesca. A child who dies of cancer. A family who found out their child's cancer returned. A family that just learned their baby has cancer. We aren't doing enough. It makes me so angry we don't treat this like an emergency.

[Amanda Haddock 🧬 @AmandaHaddock]

This is Raylin. She has #DIPG, and wants to meet @itsjojosiwa . I believe in the power of Twitter! Let’s do this! #buggysdreamcometrue

[Geraldine O'Sullivan Coyne @geosullivanc]

Upcoming phase III study of selumetinib in adult patients with NF1 and symptomatic inoperable plexiform neurofibromas #nfcon2021 @NCI_CCR_PedOnc @ChildrensTumor #RareDisease #NCIDTC @NCItreatment

[Brian Crompton @bdcrompton]

Super excited to share this publication - a 7+ year journey of discovery, started when I was a post-doc and driven home by the exceptional Dr. Biniam Adane in the Stegmaier lab @DFBC_PedCare. Loss of STAG2 rewires Ewing Sarcoma transcriptional programs: https://t.co/GbQpN3k7Ra

[Stefan Fröhling @StefanFrohling]

We are excited to see this work published and hope it will help improve our understanding and clinical management of #RareCancers such as bone and soft-tissue #Sarcoma. Please get in touch if you are interested in collaborating with us!

[The Children's Cancer Foundation, Inc. @CCFtoday]

Right now, @rtsundby is sharing his research on #neurofibromatosis at the 5th Annual Children's Cancer Foundation's Research Symposium. Local #pediatriccancer researchers will speak LIVE all day today - Join now: https://t.co/XunkZHUZ9O

[Eytan Ruppin, MD, PhD @EytanRuppin]

Excited to share our new preprint identifying the immune determinants of the association between tumor mutational burden and immunotherapy response across cancer types. An effort lead by @neelamsinha05 @Sanjusinha7 🧵 1/13 https://t.co/8aZQQ5g9Zw

[ShenAthletics @ShenAthletics]

What a great moment to see Senior Yeva Klingbeil at today’s girls track & field meet. Yeva’s teammates help her across the line in the 4X1 relay. Yeva continues her fight with cancer and we continue to be amazed by her spirit!! @CoachCloutier @ShenNews @Agostinoni_Ron

[British Journal of Cancer @BrJCancer]

📣@danalynnecasey et al. found pediatric sarcomas with TP53 mutations to be associated with a radioresistant phenotype, highlighting the critical need for further investigation of novel therapeutic strategies - published today

https://t.co/VSHbcWNNxN

#Cancergenomics

[Taylor Sundby, MD 🧬 @rtsundby]

14/14 In the future, @jack_shern, @AngelaHirbe and @aadel_chaudhuri’s labs’ findings could form the basis for improved early cancer detection and monitoring in high-risk cancer-predisposed populations! @CCFtoday @theNCI @WashUGenetics @WashUDPS @OncoAlert @WashURadOnc #sarcoma